Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
The Lancet. Haematology|July 3, 2025
Off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy in relapsed or refractory B-cell lymphoma: a multicentre, open-label, phase 1 studyPaolo Strati, Januario Castro, Aaron Goodman, et al.
Journal of Virology|October 20, 2017
Foamy Virus Vector Carries a Strong Insulator in Its Long Terminal Repeat Which Reduces Its Genotoxic PotentialMichael Aaron Goodman, Paritha Arumugam, Devin Marie Pillis, et al.
International Journal of Cancer|November 30, 2019
Prognostic implications of RAS alterations in diverse malignancies and impact of targeted therapiesShumei Kato, Ryosuke Okamura, Jason K Sicklick, et al.
British Journal of Haematology|January 2, 2026
Inconsistent definitions of transplant ineligibility in multiple myeloma: A systematic reviewKarun Neupane, Mitch Singstock, Darshi Shah, et al.
Evolution; International Journal of Organic Evolution|July 17, 2025
Elevational and Oceanic Barriers Shape the Distribution, Dispersal and Diversity of Aotearoa's Kapokapowai (Uropetala) DragonfliesEthan R Tolman, Christopher D Beatty, Aaron Goodman, et al.
Blood Advances|June 24, 2025
A prospective clinical trial of GVHD prophylaxis with posttransplant cyclophosphamide and abataceptDivya Koura, Kaitlyn Dykes, Aaron Goodman, et al.
BMC Ecology and Evolution|July 8, 2025
The blueprint for survival: the blue dasher dragonfly as a model for urban adaptationEthan R Tolman, Ellie Gamett, Christopher D Beatty, et al.
British Journal of Haematology|February 17, 2022
Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agentSandy On, Carolyn G Rath, Michelle Lan, et al.
American Journal of Hematology|September 7, 2020
Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman diseaseDavid C Fajgenbaum, David Wu, Aaron Goodman, et al.
Nature Communications|October 3, 2020
Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategyShumei Kato, Ki Hwan Kim, Hyo Jeong Lim, et al.
Pageof 5